BTK and B-cell chronic lymphocytic leukemia: Although both LUX and IB are potent inhibitors of recombinant forms of BTK, and of cells engineered to express wild type and some mutant forms of this enzyme, they have different efficacy profiles as observed in studies of LUX in xenograft models and in initial clinical trials in patients with CLL and lymphomas [25, 35].